Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
https://doi.org/10.36377/1683-2981-2021-19-4-343-349
Abstract
Relevance. The effect of a tissue engineering construct based on synthetic octacalcium phosphate activated with pDNA-encoding VEGF on bone morphogenesis at the jaw defect sites of patients was studied. It is shown that the studied osteoplastic material stimulates osteogenesis pathways already at early stages, and xenogenic hydroxyapatite, triggers osteogenesis processes with considerable delay and does not have time to form a full-fledged bone structure by 6 months.
Aim. Evaluate the dynamics of reparative osteogenesis based on the results of histomorphometric diagnostics in patients with defects in the jaw bones of various configurations and lengths with an implanted bone matrix based on synthetic octacalcium phosphate activated with pDNA-encoding VEGF.
Materials and methods. Histomorphological examination of bone tissue biopsy of jaws was carried out in 20 patients of both genders, who needed additional volume of bone tissue to install dental implantation. Patients were divided into 2 groups by type of grafted material. 6 months after the surgery, bone biopsies were taken from the bone sites at the stage of implant placement. Histomorphological patterns and histotopograms were studied in bone biopcies.
Results. In bone tissue biopsies of patients implanted with a tissue engineering construct based on synthetic octacalcium phosphate activated with pDNA-encoding VEGF, it was revealed that after 6 months there was prevaluation of mature bone tissue (42,71%), with the proportion of differentiated plate bone tissue being ~ 90%.
Conclusions. Histomorphometric analysis showed that in patients implanted with a tissue engineering construct based on synthetic octacalcium phosphate pDNA-encoding VEGF, after 6 months, early rearrangement of bone tissue into a mechanically dense and highly mineralized structure was detected.
About the Authors
G. A. Volozhin
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Russian Federation
Russian Federation
Candidate of medical science, Associate Professor of the Department of Oral Surgery, Senior Researcher, Laboratory of Medical Cybernetics and Digital Biomedical Nanotechnologies
Moscow
E. A. Bazikian
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Russian Federation
Russian Federation
Honored Doctor of the Russian Federation, Doctor of Medicine, Professor, Head of the Department of Oral Surgery, Head of the Laboratory of Cybernetics and Digital Biomedical Nanotechnologies
Moscow
I. E. Bozo
OOO Gistograft;
State Research Center – Burnasyan Federal Medical
Russian Federation
Russian Federation
Candidate of Medical Sciences, MBA, Maxillofacial Surgeon, Department of Maxillofacial and Osteoplastic Surgery, Federal Medical Biophysical Center named after A.I. Burnazyan FMBA of Russia; General Director of LLC "Histograft"
E. V. Presnyakov
North-Western State Medical University named after I.I. Mechnikov
Russian Federation
Russian Federation
Clinical resident of the Department of Pathological Anatomy, Saint Petersburg, Russia
R. V. Deev
North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg, Russia
Russian Federation
Russian Federation
Candidate of Medical Sciences, Associate Professor, Head of the Department of Pathological Anatomy,
References
1. Laurencin CT, Ambrosio AM, Borden MD, Cooper JA. Tissue engineering: orthopedic applications. Annu Rev Biomed Eng. 1999;1:19–46.
2. Laurencin CT, Khan Y, El-Amin SF. Bone graft substitutes. Expert Rev Med Devices. 2006;3(1):49–57.
3. Nukavarapu SP, Wallace J, Elgendy H, Lieberman J, Laurencin CT. Bone and biomaterials. In: group TF, editor. An introduction to biomaterials and their applications. 2 ed. CRC Press; 2011. pp. 571– 593.
4. Baroli B. From natural bone grafts to tissue engineering therapeutics: brainstorming on pharmaceutical formulative requirements and challenges. J Pharm Sci. 2009;98(4):1317–1375.
5. O’Keefe RJ, Mao J. Bone tissue engineering and regeneration: from discovery to the clinic--an overview. Tissue Eng Part B Rev. 2011;17(6):389–392.
6. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62.
7. Zisch AH, Lutolf MP, Ehrbar M, Raeber GP, Rizzi SC, Davies N, et al. Cell-demanded release of VEGF from synthetic, biointeractive cell ingrowth matrices for vascularized tissue growth. FASEB J. 2003;17(15):2260–2262.
8. Ehrbar M, Djonov VG, Schnell C, Tschanz SA, Martiny-Baron G, Schenk U, et al. Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. Circ Res. 2004;94(8):1124–1132.
Review
For citations:
Volozhin G.A., Bazikian E.A., Bozo I.E., Presnyakov E.V., Deev R.V. Moscow State University of Medicine and Dentistry named after A.I. Evdokimov. Endodontics Today. 2021;19(4):343-349. (In Russ.) https://doi.org/10.36377/1683-2981-2021-19-4-343-349
Email this article 